Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
SCOTTSDALE, Ariz. - Carlisle Companies Incorporated (NYSE:CSL), a $16.46 billion market cap company known for its building envelope products, announced a dividend of $1.00 per share to be paid out on June 2, 2025. Shareholders on record by May 19, 2025, will be eligible for the dividend, representing a 1.06% yield. According to InvestingPro, CSL has maintained dividend payments for 55 consecutive years and raised them for 32 straight years.
The company, which operates through its Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT) businesses, is recognized for providing energy-efficient solutions in the building sector. With annual revenue of $5 billion and a strong current ratio of 2.58, Carlisle’s approach to business includes a commitment to driving shareholder value and a balanced capital strategy that encompasses business investments, strategic acquisitions, share repurchases, and consistent dividend growth. InvestingPro analysis suggests the stock is currently trading below its Fair Value, making it an interesting opportunity for value investors.
In line with its continuous improvement philosophy, encapsulated in the Carlisle Operating System (COS), the company aims to reach net-zero greenhouse gas emissions by the year 2050. This initiative is part of Carlisle’s broader commitment to environmental responsibility and innovation in its product offerings and operational practices.
The declaration of the dividend reflects Carlisle’s financial health and its ability to return value to its shareholders. It is a continuation of the company’s practice of sharing profits with its investors while simultaneously investing in sustainable growth and operational excellence.
The dividend announcement is based on a press release statement from Carlisle Companies Incorporated.
In other recent news, Carlisle Companies Incorporated reported its first-quarter 2025 earnings, revealing an adjusted earnings per share (EPS) of $3.61, surpassing analysts’ expectations of $3.48. The company achieved revenue of $1.1 billion, which was in line with forecasts. Despite flat revenue growth, Carlisle’s performance demonstrated resilience, with effective cost management contributing to the EPS beat. Meanwhile, the European Commission granted standard marketing authorization to FILSPARI, a drug developed by Travere Therapeutics and CSL Vifor, for the treatment of IgA nephropathy (IgAN) in Europe. This approval is based on the successful results from the Phase 3 PROTECT Study, and Travere Therapeutics anticipates a $17.5 million milestone payment from CSL Vifor. Carlisle Companies also maintained its focus on innovation and capital return, with plans to achieve mid-single-digit revenue growth and an expansion in EBITDA margin. The company continues to lead in North America’s building products sector, particularly in roofing membranes and architectural metals. These developments reflect significant strides made by both Carlisle Companies and Travere Therapeutics in their respective fields.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.